ERBB2 and ductal breast carcinoma in situ: A potential connection with JAM-A is of importance since high HER2 expression has been suggested to flag DCIS tumors that progress to invasive disease [14]; if JAM-A is indeed an upstream regulator of HER2, this might suggest its druggability in HER2-positive breast cancer.